JW Pharmaceutical Corp - Asset Resilience Ratio
JW Pharmaceutical Corp (001067) has an Asset Resilience Ratio of 8.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check JW Pharmaceutical Corp strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how JW Pharmaceutical Corp's Asset Resilience Ratio has changed over time. See net asset quality index of JW Pharmaceutical Corp to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down JW Pharmaceutical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see JW Pharmaceutical Corp market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩49.95 Billion | 8.17% |
| Total Liquid Assets | ₩49.95 Billion | 8.17% |
Asset Resilience Insights
- Limited Liquidity: JW Pharmaceutical Corp maintains only 8.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
JW Pharmaceutical Corp Industry Peers by Asset Resilience Ratio
Compare JW Pharmaceutical Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual Asset Resilience Ratio data for JW Pharmaceutical Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.66% | ₩22.12 Billion ≈ $14.99 Million |
₩604.60 Billion ≈ $409.73 Million |
-8.48pp |
| 2023-12-31 | 12.14% | ₩78.29 Billion ≈ $53.05 Million |
₩645.04 Billion ≈ $437.13 Million |
-6.30pp |
| 2022-12-31 | 18.44% | ₩115.78 Billion ≈ $78.46 Million |
₩627.97 Billion ≈ $425.57 Million |
+13.34pp |
| 2021-12-31 | 5.10% | ₩32.30 Billion ≈ $21.89 Million |
₩633.05 Billion ≈ $429.01 Million |
-3.06pp |
| 2020-12-31 | 8.17% | ₩44.84 Billion ≈ $30.39 Million |
₩549.09 Billion ≈ $372.11 Million |
+8.16pp |
| 2016-12-31 | 0.00% | ₩20.00 Million ≈ $13.55K |
₩651.08 Billion ≈ $441.23 Million |
0.00pp |
| 2015-12-31 | 0.00% | ₩30.00 Million ≈ $20.33K |
₩613.48 Billion ≈ $415.75 Million |
0.00pp |
| 2014-12-31 | 0.01% | ₩30.00 Million ≈ $20.33K |
₩589.24 Billion ≈ $399.32 Million |
-- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more